ARTRYA LIMITED — Capital/Financing Update 2025

Oct 2, 2025

Coronary Artery Disease. We see you.

==> picture [612 x 14] intentionally omitted <==

==> picture [108 x 20] intentionally omitted <==

COMPLETION OF SHARE PURCHASE PLAN

PERTH, Australia, 3 October 2025: Artrya Limited (ASX: AYA) ( Artrya or the Company ), a medical technology company commercialising its Salix[®] AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to advise the final results of the Share Purchase Plan ( SPP ) which opened on 15 September 2025.

The SPP was strongly supported and closed early on 26 September 2025 significantly oversubscribed. Eligible applications received totalled approximately A$8.7 million.

The Company aimed to raise approximately A$5 million and has scaled back eligible applications on a pro-rata basis to that level. The scale back methodology implemented was designed to provide an equitable outcome for shareholders. Accordingly, a total of 2,438,872 new fully paid ordinary shares in the capital of Company ( Shares ) will be issued pursuant to the SPP, for total proceeds of approximately A$5 million (before costs).

The strong support for the SPP follows the successful A$75 million placement announced to the ASX on 9 September 2025. The SPP offered all eligible shareholders the opportunity to acquire Shares at $2.05 each, which is the same price as the placement.

An Appendix 2A in respect of the SPP Shares follows this announcement.

Excess application money resulting from the scale back will be refunded to applicants in accordance with the terms of the SPP. To facilitate the timely provision of any refunds, the Company encourages applicants to the SPP to ensure their direct credit details are provided online with Automic Share Registry via the Investor Portal at https://portal.automic.com.au/investor/home as soon as possible. For assistance, please contact Automic at 1300 288 664 (within Australia), +61 2 9698 5414 (international) between 6:30am to 5:00pm (AWST) on business days, or email corporate.actions@automicgroup.com.au.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Artrya Limited I ACN 624 005 741 I 1257 Hay Street, West Perth Western Australia 6005 AUSTRALIA www.artrya.com

==> picture [612 x 15] intentionally omitted <==

==> picture [93 x 19] intentionally omitted <==

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information ( Estimates and Projections ). Forward-looking statements can generally be identified by the use of forwardlooking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

Investor & Media Enquiries

John Konstantopoulos Co-Founder and Chief Executive Officer Tel: +61 8 6478 7816 Email: contact@artrya.com

David Allen or John Granger Hawkesbury Partners Tel: +61 499 100 038 or +61 410 577 155 Email: investors@artrya.com

Artrya Limited I ACN 624 005 741 I 1257 Hay Street, West Perth Western Australia 6005 AUSTRALIA www.artrya.com

2